These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 16168052)

  • 1. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
    Heald M; Cawthorne MA
    Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
    Grygiel-Górniak B
    Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A; Chew GT; Watts GF
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
    Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
    Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
    Node K; Inoue T; Boyko V; Goldberg I; Fisman EZ; Adler Y; Schwammenthal E; Matas Z; Behar S; Tenenbaum A
    Cardiovasc Diabetol; 2009 Jan; 8():5. PubMed ID: 19173749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PPAR in cardiovascular diseases.
    Das SK; Chakrabarti R
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):193-209. PubMed ID: 18221086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.